Alexion Pharmaceuticals Inc represents values of innovation, patient focus, and scientific excellence. With a corporate philosophy centered on serving patients with rare and devastating diseases, Alexion strives to develop and deliver life-transforming therapies. Their commitment to patients is reflected in their unwavering dedication to advancing medical research and pushing the boundaries of scientific discovery. Through collaborations and partnerships, Alexion aims to provide hope and improve the lives of those affected by rare diseases. As a leader in the biopharmaceutical industry, Alexion Pharmaceuticals Inc continues to make significant contributions to the healthcare community globally.

Alexion Pharmaceuticals Inc is primarily present in various countries and regions around the world. The company operates in the United States, where its headquarters are located. Additionally, Alexion Pharmaceuticals Inc has a substantial presence in Europe, including countries such as Germany, France, Italy, Spain, and the United Kingdom. The company also has operations in Canada, Australia, and Japan. With its global presence, Alexion Pharmaceuticals Inc aims to provide innovative therapies and solutions to patients across different regions, contributing to improved healthcare outcomes worldwide.

Alexion Pharmaceuticals Inc has achieved multiple significant milestones throughout its history. Notably, the company gained approval for its flagship drug Soliris, which revolutionized the treatment of rare and devastating diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Additionally, Alexion expanded its product portfolio by launching Ultomiris, a long-acting C5 complement inhibitor. Moreover, the company successfully acquired Synageva BioPharma Corp, enhancing its position in the rare disease space. With a commitment to innovation, research, and patient care, Alexion Pharmaceuticals Inc continues to make strides in transforming patients' lives.

Alexion Pharmaceuticals Inc is a renowned biopharmaceutical company with a rich history and background. Founded in 1992, the company is dedicated to developing innovative therapies for patients with rare and severe diseases. Alexion has a strong focus on complement biology and has successfully introduced breakthrough treatments that have transformed the lives of many patients worldwide. With its headquarters in Boston, Massachusetts, and a global presence, Alexion continues to push the boundaries of scientific research and development in order to bring hope and improved quality of life to those in need. The dedication and expertise of the team at Alexion Pharmaceuticals Inc have made them a leading force in the field of rare disease therapies.

The main competitors of Alexion Pharmaceuticals Inc in the market are AbbVie Inc, Amgen Inc, Biogen Inc, Gilead Sciences Inc, and Regeneron Pharmaceuticals Inc.

Alexion Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries. As a leading company, Alexion Pharmaceuticals Inc specializes in developing and delivering life-transforming therapies for patients with severe and rare diseases. With its focus on innovation and research, Alexion Pharmaceuticals Inc has established itself as a prominent player in the healthcare sector. Its dedication to addressing unmet medical needs and improving patient outcomes has made Alexion Pharmaceuticals Inc a trusted name in the industry.

The business model of Alexion Pharmaceuticals Inc. focuses on developing and commercializing life-transforming therapies for patients with rare diseases. As a global biopharmaceutical company, Alexion is committed to addressing the unmet medical needs of individuals affected by severe and rare disorders. With a strong emphasis on research, innovation, and patient-centricity, Alexion combines cutting-edge science with a deep understanding of rare diseases to deliver breakthrough therapies. Through its unique approach, the company aims to improve the lives of patients and provide hope for those living with rare conditions.

P/E odnos Alexion Pharmaceuticals iznosi 10,15.

KUV kompanije Alexion Pharmaceuticals iznosi 4,99.

AlleAktien kvalitativni skor za Alexion Pharmaceuticals je 9/10.

očekivana Alexion Pharmaceuticals promet je 8,11 milijardi USD.

Dobit očekivana Alexion Pharmaceuticals je 3,99 milijardi USD.

Alexion Pharmaceuticals Inc is a global biopharmaceutical company that focuses on rare diseases. The company specializes in developing therapies for patients with rare genetic disorders and other serious illnesses that affect the immune system. Alexion pursues a forward-thinking business model aimed at innovation and expansion strategies to further build and diversify its portfolio. The main business areas of Alexion Pharmaceuticals include: 1. Orphan Diseases - Alexion focuses on disorders that affect fewer than 200,000 patients in the United States, utilizing their deep understanding of the human protein system to develop new therapies and save lives. The company currently has various successful products for rare diseases in its portfolio, including the C5 complement inhibitor Soliris, the drug Ultomiris, and the polyethylene glycol hemophilia B product Strensiq. 2. Neurology - In December 2019, Alexion Pharmaceuticals announced its intention to expand its portfolio to include neurological disorders. The company currently has early and late-phase clinical trials for various novel treatment methods, including therapies for myasthenia gravis, neuromuscular disorders, and cerebral infarction. 3. Oncology - Although Alexion products are not directly effective in the field of oncology, the company has developed a platform for the discovery of targeted antibodies against medically significant targets. Alexion is currently collaborating with leading biotech companies and academic institutions to make further groundbreaking discoveries. The company has several innovative products in the clinical stage with excellent chances of success. Soliris, Alexion's first approved C5 complement inhibitor, is currently approved in over 55 countries. This therapy is used in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome, and hemolytic anemia. The drug is also currently being studied in clinical trials for patients with neuromuscular disorders, and it has recently been used against Covid-19. Ultomiris, the next generation of Soliris, is a long-acting C5 inhibitor that is subcutaneously injected every 8 weeks, unlike Soliris, which requires weekly administration. The drug has shown efficacy in patients who were already on Soliris therapy. Ultomiris is currently approved for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic-uremic syndrome. Strensiq, a recombinant enzyme, was specifically developed for patients with rare bone diseases such as hypophosphatasia. It enables. Alexion Pharmaceuticals pursues a strategy of financial stability and profitable development. The company aims to achieve technological superiority through smart investments in research and development, expand into new therapeutic patient populations, and seek geographic expansion and diversification. Through its intensive research activities, Alexion Pharmaceuticals continues to develop innovative and groundbreaking products to improve the lives of patients with rare and serious diseases. Translation: Alexion Pharmaceuticals Inc is a global biopharmaceutical company specializing in rare diseases. It develops therapies for patients with rare genetic disorders and other serious immune system illnesses. With a focus on innovation and expansion, the company aims to build and diversify its portfolio. Alexion's main business areas are orphan diseases, neurology, and oncology. It has successful products for rare diseases, such as Soliris, Ultomiris, and Strensiq. Alexion is also involved in clinical trials for innovative treatments in neurology. Although it doesn't directly impact oncology, it collaborates with biotech companies and academic institutions for targeted antibody discoveries. Financial stability and profitable development are prioritized, with investments in research and development and geographic expansion. Through its research efforts, Alexion strives to improve the lives of patients with rare and serious diseases.

Alexion Pharmaceuticals isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Alexion Pharmaceuticals trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Alexion Pharmaceuticals je US0153511094.

WKN od Alexion Pharmaceuticals je 899527.

Oznaka za praćenje akcija kompanije Alexion Pharmaceuticals je ALXN.

U poslednjih 12 meseci, Alexion Pharmaceuticals je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Alexion Pharmaceuticals će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Alexion Pharmaceuticals trenutno iznosi .

Alexion Pharmaceuticals isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Alexion Pharmaceuticals je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Alexion Pharmaceuticals se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Alexion Pharmaceuticals od 2. 10. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 2. 10. 2024..

Isplata poslednje dividende izvršena je 2. 10. 2024..

U godini 2023 kompanija Alexion Pharmaceuticals je isplatila 0 USD kao dividende.

Dividende od Alexion Pharmaceuticals se isplaćuju u USD.